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Cold War Era (1946–1991) was marked by the presence of two distinctively different
economic systems, namely the free-market (The Western ones) and central-planned
(The Eastern ones) economies. The main goal of this study refers to the exploration of
development pathways of Public and Private Health Expenditure in all of the countries of
the European WHO Region. Based on the availability of fully comparable data from the
National Health Accounts system, we adopted the 1995–2014 time horizon. All countries
were divided into two groups: those defined in 1989 as free market economies and those
defined as centrally-planned economies. We observed six major health expenditures:
Total Health Expenditure (% of GDP), Total Health Expenditure (PPP unit), General
government expenditure on health (PPP), Private expenditure on health (PPP), Social
security funds (PPP) and Out-of-pocket expenditure (PPP). All of the numerical values
used refer exclusively to per capita health spending. In a time-window from the middle of
the 1990s towards recent years, total health expenditure was rising fast in both groups
of countries. Expenditure on health % of GDP in both group of countries increased over
time with the increase in the Free-market economies seen to be more rapid. The steeper
level of total expenditure on health for the Free-market as of 1989 market economies,
is due mainly to a steep increase in both the government and private expenditure on
health relative to spending by centrally-planned economies as of the same date, with the
out-of-pocket expenditure and the social security funds in the same market economies
category following the same steepness. Variety of governments were leading Eastern
European countries into their transitional health care reforms. We may confirm clear
presence of obvious divergent upward trends in total governmental and private health
expenditures between these two groups of countries over the past two decades. The
degree of challenge to the fiscal sustainability of these health systems will have to be
judged for each single nation, in line with its own local circumstances and perspectives.
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INTRODUCTION
Evolution of health care associated expenditure in Europe
(1), like elsewhere, was closely related to the geopolitical and
economic realities on the continent (2). Cold War Era lasting
approximately from 1946–1991 was marked by the presence of
two distinctively different economic systems, namely the free-
market and central-planned economies. These two patterns of
governance had also profoundly different views over the societal
role of health care (3).
The Western ones, led by the USA, were so called free-
market economies and their dominant social theory ultimately
leading to the rise of neoliberal capitalism. In health care, a
variety of models were deployed but Beveridge and Bismarck
models of health care financing and provision were the most
broadly accepted (4). It is very important to emphasize that the
return on investment in health care and the role of population
health in societal economic productivity were well understood
very early on by the prominent Western health economists (5).
This knowledge was later on successfully introduced into the
social policy. The level of medical technology and innovation,
with few exceptions among some disciplines, tended to be higher
compared to the East. However major weaknesses of these
systems were rather significant, with social inequities in terms
of access to medical care and affordability. These inequities, in
some leading Western health systems (6), became even deeper
with the accelerated globalization (7) that followed after the end
of the Cold War.
The Eastern ones, led by the USSR, were presented by
centrally-planned socialist economies that were rooted inMarxist
social theory. The Soviet Semashko model of health care
financing and provision prevailed in these countries. To its
great historical credit, it is recognized to be the first one to
globally deliver universal health coverage back in the early
1930s at the level of medical technology of that time. Even
the poorest citizens had the right to state-funded basic medical
care (8). After WWII, the famous Five-year plans led to rapid
industrialization in USSR and some of its client states. This
ultimately established USSR as the second ranked economy
globally (9) for the most of Cold War Era duration (10). It
is important to notice that both health care and education
were regarded as purely consumption branches of the overall
economy (11). They were assigned limited resources unlike some
industrial priority areas believed to be far more productive
in bringing budgetary revenues (12). This causal link between
population health and social economic productivity was not well
understood, and in reality not even exploited.Medical technology
development and pace of innovation, with limited exceptions in
some cutting-edge disciplines [psychiatry (13), orthopedic (14)
and eye surgery (15), cosmic (16), aeronautic and alternative
medicine (17) to mention a few (18)] were lagging behind vis-à-
vis the West (19). However the social justice system in the East
was exceptionally efficient (20). Poverty was almost eradicated
and social inequalities in terms of access to state-funded health
care were far lower compared to theWestern ones (21). The scale
of corruption and informal payments within the health system at
that time were controlled and rather low (22). These countries
became heavily industrialized, characterized by massive rural-
urban migration and morbidity and mortality structures were
similar to theWest (23). Although the pool of maternal mortality
was liquidated (24) and early childhood survival (25) improved
rapidly in early post-WWII decades (26), overall life expectancy
was lagging significantly behind the top performing free market
economies (27).
METHODS
The main goal of this study refers to the exploration of
development pathways of Public and Private Health Expenditure
in all of the countries of the European WHO Region following
their different starting points back in time at the end of the Cold
War Era (28). Back in 1991 free-market economies continued
evolving their traditions further and accelerated globalization
was one of the main changes affecting health policy challenges.
Unlike them, since 1991 Central and Eastern European centrally
planned socialist economies underwent profound and complex
socioeconomic and health care reforms. Their aim was to convert
old socialist into a new capitalism grounded economic system
(29). At the same time, mostly less efficient, massive, hospital,
curative-oriented health systems had to be changed into the
lighter and less costly ones based on preventive medicine (30)
and outpatient care (31). These processes of social change
became broadly known as the “Eastern European Transition”
(32). In some countries of the region, they came almost to
an end in 2017, while in others they continued with less
or more significant changes of health policy and financing
traditions. It should be noted that some countries of this region
among the Commonwealth of Independent Nations (CIS) led
by Russian Federation, after the early attempts in 1990s (33),
have willingly abandoned such transition and adopted their own
distinctive model of development, based on Semashko traditions
(34).
Based on the availability of fully comparable data from the
National Health Accounts system (35) introduced by WHO,
we adopted the 1995–2014 time horizon. After thorough
consideration of several public registries issued by the UN,
OECD, World Bank, EuroStat and other multilateral agencies,
we decided that the Global Health Expenditure Database
will be our sole source of data for this study (36). We
took the end of the Cold War as a point in time when
initially divergent economic models began to converge in
certain number of countries. What we wanted to show is
that even today, after two and a half decades of “transition,”
countries eastern from the Iron Curtain still in many core
indicators of health spending are closer to their Semashko root
than to the Western Bismarck/Beveridge model like in the
pharmaceutical spending for example the studies of Álvarez-
Gálvez,and Jaime-Castillo in 2018 (37). Although, divergency
began in 1917 after the Revolution, during the Westfallen peace
in between two world wars most of Central Europe was still
capitalist.
The initial set of observed variables comprised of ten different
health spending indicators: Public funds, Rest of the world
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funds / External resources, Total expenditure on health, General
government expenditure on health, Ministry of Health, Social
security funds, Private expenditure on health, Private insurance,
Out-of-pocket expenditure and Non-profit institutions serving
households (e.g., NGOs). However, after a pilot extraction of
data was done, we noticed significant gaps in both chronology
and geographical coverage. These could not be addressed with
any valid statistical missing data handling strategy. Therefore, we
shortlisted the final count to the six major health expenditures,
all of which were broadly presented and available: Total Health
Expenditure (% of GDP), Total Health Expenditure (PPP
unit), General government expenditure on health (PPP), Private
expenditure on health (PPP), Social security funds (PPP), and
Out-of-pocket expenditure (PPP). All of the numerical values
used refer exclusively to per capita health spending in order
to eliminate the bias arising from any nation’s population
size.
Using the premise of this observation, all countries were
divided into two groups: those defined in 1989 as free market
economies and those defined as centrally-planned economies.
With the exception of Eastern Germany after reunification,
data on all other UN recognized countries were accessible
regardless of the changes of borders and statehoods in Central
and Eastern Europe (38). A clear list of countries in both
groups can be found in Table 1 below. Moreover, Table 2
below, shows the data for each individual country within both
groups.
STATISTICAL ANALYSIS
We then conducted a comparative statistical analysis on two
time cross sections, comparing these two groups of countries
for the period 1995–2014. Another part of the analysis refers to
comparison of the time trend between the groups. For the first
case, the Mann-Whitney U Test was applied and in another case
we decided for the Wilcoxson’s test, because our data did not
fulfill parametric conditions for a normal (Gauss’) distribution.
We checked this fact with the Shapiro-Wilk test.
STUDY LIMITATIONS
This study presents a retrospectively designed research on
aggregate national level data. Such data are being reported by
the national authorities, such as governments and ministries
of health to the respective UN and WHO offices. Authors
take data as guaranteed by the national governments and
checked by WHO European Office and are not capable of
checking reliability, consistency of such reporting or the internal
accounting systems which may slightly vary from country to
country. This way of tracking and reporting financial flows
within the nation’s health system have been made as much
consistent as possible through the lengthy process of WHO
initiated introduction of the National Health Accounts in the
early 1990s (39). It assumed mandatory staff trainings and
capacity building by the health insurance funds’ and ministry
of health officials exactly for the purpose to make these follow
TABLE 1 | Division of European countries based on their economic system at the
end of Cold War Era back in 1989.
Free market economies as of 1989 Centrally planned economies as of
1989
Andorra
Austria
Belgium
Cyprus
Denmark
Finland
France
Germany
Greece
Iceland
Ireland
Israel
Italy
Luxembourg
Malta
Monaco
Netherlands
Norway
Portugal
San Marino
Spain
Sweden
Switzerland
Turkey
United Kingdom of Great Britain and
Northern Ireland
Albania
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Bulgaria
Croatia
Czech Republic
Estonia
Georgia
Hungary
Kazakhstan
Kyrgyzstan
Latvia
Lithuania
Montenegro
Poland
Republic of Moldova
Romania
Russian Federation
Serbia
Slovakia
Slovenia
Tajikistan
The former Yugoslav Republic of
Macedonia
Turkmenistan
Ukraine
Uzbekistan
the unique patterns and indicator definitions that have been
adopted during the establishment of the NHA system by all
the representatives of all the country members of the United
Nations.
Other possible limitations refer to the fact that this is a purely
health economic observation. While conducting this study, we
were focused on the different dimensions of health expenditures
of given European nations while using only six core indicators
and only two units of measurement (THE as % of GDP and PPP)
out of many currency units available in a given database (40).
If we had opted to observe country group parities in nominal
dollar terms, landscape might have looked quite different (41).
However, we followed the ground health economics theory
that says that purchasing power parity allows the best possible
comparison among the nations with significantly different levels
of income/industrial development (42). Likewise, observation
of total health expenditure expressed as percentage point share
of gross domestic product was selected, because according to
broadly accepted economic theory, this indicator is the only
one allowing us transnational comparisons among inherently
different economic systems (43).
Based on data we worked with, there is no evidence for
definite conclusions on effectiveness and performance of these
national health systems in terms of their public health output.
We did not use, nor consider data such as longevity, morbidity,
mortality, utilization of medical services or medicines or any
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TABLE 2 | The data for each individual country within both groups.
Median (95%
confidence
intervals)
Total expenditure on
health (% of GDP)
Total expenditure on
health in current PPP
per capita
General government
expenditure on
health in current PPP
per capita
Private expenditure
on health in current
PPP per capita
Out of pocket
expenditure in
current PPP per
capita
Social security funds
in current PPP per
capita
FREE MARKET ECONOMIES AS OF 1989 (1995–2014)
Andorra 6.1
(6.0–7.3)
2259.7
(2146.2–3028.5)
1587.4
(1507.4–2293.1)
717.9
(627.0–747.2)
519.7
(444.9–538.3)
1222.6
(1170.5–1712.5)
Austria 10.4
(10.2–10.7)
3517.7
(3203.0–4011.7)
2605.8
(2394.2–3019.4)
912.0
(807.4–993.7)
613.9
(514.8–658.5)
1516.6
(1382.2–1712.2)
Belgium 9.2
(8.7–9.6)
2949.7
(2601.4–3406.7)
2262.7
(1977.4–2616.1)
706.8
(622.6–792.0)
559.1
(503.6–633.7)
1931.4
(1686.7–2238.2)
Cyprus 6.3
(6.0–6.8)
1555.4
(1340.1–1828.9)
671.8
(567.9–811.9)
889.8
(769.5–1015.4)
727.5
(691.1–883.0)
–
Denmark 9.7
(9.2–10.2)
3188.3
(2899.9–3815.4)
2690.1
(2438.0–3235.2)
498.2
(461.7–580.5)
450.6
(417.0–515.9)
–
Finland 8.2
(8.0–8.6)
2525.2
(2220.0–2911.2)
1857.5
(1626.0–2167.9)
667.6
(593.8–743.6)
512.1
(457.5–561.7)
373.2
(312.6–413.9)
France 10.5
(10.3–10.8)
3159.9
(2885.6–3597.1)
2462.9
(2266.6–2799.4)
697.0
(615.3–785.5)
221.9
(205.7–251.7)
2357.3
(2149.4–2661.6)
Germany 10.4
(10.2–10.7)
3283.7
(3076.4–3891.5)
2504.8
(2404.6–2993.1)
780.1
(670.5–899.6)
458.0
(381.4–517.2)
2190.9
(2095.2–2640.2)
Greece 8.7
(8.5–9.1)
2096.9
(1837.3–2343.5)
1266.4
(1090.0–1475.4)
810.5
(734.2–878.5)
710.1
(648.0–784.5)
642.5
(494.4–791.9)
Iceland 8.9
(8.7–9.2)
3338.7
(2842.2–3357.9)
2728.0
(2323.4–2735.0)
600.0
(517.5–624.2)
550.8
(486.5–577.8)
910.9
(780.2–937.6)
Ireland 7.2
(6.9–7.8)
2901.8
(2306.3–3204.3)
2208.6
(1685.3–2303.6)
693.1
(609.6–912.1)
451.0
(362.6–525.1)
14.1
(11.4–16.7)
Israel 7.4
(7.4–7.5)
1871.6
(1785.1–2074.6)
1174.6
(1131.1–1292.9)
678.9
(620.2–764.8)
512.7
(472.9–549.9)
826.4
(818.5–939.3)
Italy 8.5
(8.1–8.8)
2520.5
(2290.7–2836.1)
1913.7
(1690.4–2140.3)
608.9
(598.7–697.4)
538.5
(533.4–607.1)
2.3
(2.4–5.3)
Luxembourg 7.3
(6.7–7.5)
5420.5
(4171.4–5656.7)
4600.2
(3618.7–4831.3)
778.2
(544.5–830.2)
573.3
(415.6–599.5)
3662.8
(2938.5–3936.9)
Malta 8.2
(7.4–8.6)
1906.0
(1574.7–2206.7)
1284.2
(1057.5–1471.8)
621.8
(514.9–737.3)
536.6
(461.9–663.2)
–
Monaco 3.7
(3.5–3.9)
4269.9
(3625.2–4836.9)
3762.8
(3194.6–4266.0)
507.1
(429.8–571.7)
298.9
(253.8–338.6)
3707.6
(3140.8–4204.8)
Netherlands 8.9
(8.4–9.6)
3302.9
(2908.8–3996.6)
2236.5
(2131.6–3269.4)
673.1
(673.4–831.0)
237.0
(210.7–247.0)
2069.1
(1966.3–2981.0)
Norway 9.1
(8.6–9.2)
4204.1
(3556.6–4835.9)
3512.6
(2976.2–4080.2)
691.6
(579.4–755.9)
658.6
(551.7–716.1)
–
Portugal 9.5
(8.8–9.6)
2101.7
(1752.4–2301.8)
1472.6
(1179.9–1550.9)
629.1
(569.7–753.6)
459.2
(408.6–558.8)
–
San Marino 4.7
(4.5–5.2)
2700.7
(2626.2–3017.3)
2468.7
(2382.9–2780.1)
234.8
(227.3–253.1)
213.2
(206.4–229.8)
2468.7
(2382.9–2780.1)
Spain 8.1
(7.8–8.6)
2162.7
(1884.8–2506.1)
1562.0
(1363.9–1827.6)
600.8
(519.1–680.3)
463.8
(418.1–542.1)
134.4
(120.2–143.7)
Sweden 9.1
(8.8–10.0)
2964.9
(2696.4–3702.8)
2409.5
(2241.6–3079.7)
555.5
(450.3–627.5)
481.2
(404.2–550.7)
–
Switzerland 10.5
(10.3–10.9)
3988.9
(3723.2–4839.1)
2350.7
(2184.8–3026.8)
1638.2
(1530.6–1797.0)
1233.7
(1130.5–1361.8)
–
Turkey 5.3
(4.5–5.4)
587.1
(505.3–757.6)
407.6
(361.1–568.0)
169.2
(139.7–194.1)
125.6
(107.0–141.4)
244.8
(206.4–359.6)
United Kingdom of
Great Britain and
Northern Ireland
8.1
(7.6–8.6)
2653.1
(2189.4–2860.8)
2150.1
(1780.8–2348.2)
504.6
(403.6–514.8)
259.8
(226.8-279.2)
–
(Continued)
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TABLE 2 | Continued
Median (95%
confidence
intervals)
Total expenditure on
health (% of GDP)
Total expenditure on
health in current PPP
per capita
General government
expenditure on
health in current PPP
per capita
Private expenditure
on health in current
PPP per capita
Out of pocket
expenditure in
current PPP per
capita
Social security funds
in current PPP per
capita
CENTRALLY PLANNED ECONOMIES AS OF 1989 (1995–2014)
Albania 6.1
(6.0–6.5)
371.1
(329.8–448.8)
160.2
(128.8–204.0)
211.0
(200.6–245.3)
197.8
(196.2–240.0)
45.9
(49.1–123.1)
Armenia 5.3
(4.8–5.5)
233.8
(179.0–255.1)
73.0
(61.3–104.6)
140.8
(115.7–152.5)
134.1
(110.3–145.0)
–
Azerbaijan 5.4
(5.2–6.1)
492.0
(347.0–628.5)
59.0
(63.0–125.7)
429.8
(282.6–504.1)
384.4
(246.9–450.0)
–
Belarus 6.2
(5.9–6.4)
614.3
(491.2–726.8)
453.1
(355.5–511.2)
161.2
(132.7–218.6)
114.7
(96.0–178.3)
–
Bosnia and
Herzegovina
8.7
(8.3–9.1)
536.3
(441.6–683.7)
306.9
(267.0–458.3)
229.3
(172.1–227.9)
229.3
(170.8–224.4)
290.8
(253.9–429.7)
Bulgaria 6.8
(6.1–7.0)
686.8
(561.6–881.3)
417.6
(339.7–500.7)
268.9
(221.4–381.1)
261.3
(216.9–371.1)
–
Croatia 7.2
(6.9–7.5)
1047.0
(949.7–1324.8)
876.1
(801.2–1110.3)
166.0
(145.8–217.2)
157.2
(131.1–175.7)
790.3
(724.6–967.8)
Czech Republic 6.8
(6.7–7.1)
1434.2
(1262.5–1672.8)
1265.0
(1109.9–1430.8)
169.2
(151.7–242.9)
151.0
(142.9–223.9)
1134.3
(994.7–1298.2)
Estonia 5.8
(5.5–6.0)
786.8
(725.3–1121.9)
599.1
(573.9–879.9)
184.7
(144.1–234.3)
164.0
(132.6–221.5)
–
Georgia 8.3
(7.5–8.6)
328.6
(277.0–448.9)
57.1
(48.0–85.0)
271.5
(228.1–364.8)
253.3
(202.2–301.5)
30.1
(25.7–54.5)
Hungary 7.5
(7.3–7.7)
1381.0
(1087.6–1455.6)
955.5
(769.6–980.1)
416.7
(316.8–476.8)
346.7
(266.0–379.4)
787.8
(639.0–817.2)
Kazakhstan 4.1
(3.9–4.3)
512.0
(435.9–670.7)
291.7
(254.1–382.3)
206.3
(179.9–290.3)
203.4
(177.4–286.7)
–
Kyrgyzstan 5.9
(5.7–6.3)
120.0
(109.8–155.5)
49.0
(52.0–82.7)
70.3
(57.2–73.4)
63.3
(52.1–66.4)
–
Latvia 6.2
(6.1–6.4)
569.2
(475.7–701.0)
323.5
(278.1–424.9)
245.7
(193.7–270.5)
231.6
(185.2–256.8)
–
Lithuania 6.3
(6.1–6.5)
816.7
(749.2–1165.1)
587.1
(533.7–811.2)
257.6
(210.2–341.2)
253.7
(202.2–332.0)
468.1
(400.3–664.4)
Montenegro 7.4
(7.0–7.7)
684.0
(601.1–778.6)
485.9
(407.1–504.0)
188.6
(189.7–278.9)
188.6
(189.7–278.9)
455.0
(390.6–473.5)
Poland 6.2
(6.0–6.4)
831.8
(770.9–1134.8)
573.5
(543.5–800.9)
257.6
(226.3–332.0)
225.3
(201.5–273.2)
–
Republic of
Moldova
9.8
(8.7–10.3)
247.7
(225.5–355.9)
117.1
(113.4–173.9)
130.5
(111.3–182.8)
105.7
(91.1–150.5)
–
Romania 5.3
(4.5–5.2)
502.4
(421.7–716.1)
390.0
(336.4–574.5)
108.1
(84.5–141.6)
105.2
(83.0–138.2)
–
Russian Federation 5.9
(5.8–6.5)
573.3
(616.8–1101.4)
349.0
(371.1–616.8)
224.3
(244.8–485.5)
184.7
(203.4–444.8)
142.4
(144.0–266.0)
Serbia 8.5
(7.7–9.1)
719.6
(586.1–949.1)
484.4
(378.6–594.5)
235.1
(206.2–353.0)
206.7
(185.1–328.2)
446.2
(350.9–553.6)
Slovakia 7.1
(6.4–7.5)
1101.0
(966.7–1543.1)
815.8
(754.9–1107.9)
285.2
(209.2–437.8)
230.6
(172.8–341.9)
709.8
(696.2–1004.3)
Slovenia 8.5
(8.2–8.8)
1942.4
(1662.8–2177.5)
1423.9
(1228.8–1593.4)
520.7
(433.4–584.8)
233.5
(196.0–260.4)
1303.8
(1128.5–1447.9)
Tajikistan 5.2
(4.5–5.6)
81.0
(62.2–106.7)
15.4
(15.6–28.6)
65.6
(46.3–78.4)
63.6
(43.7–71.2)
–
The former
Yugoslav Republic
of Macedonia
8.1
(7.4–8.4)
638.5
(578.2–694.5)
378.2
(353.9–442.3)
240.6
(220.9–255.5)
240.6
(220.9–255.5)
365.1
(337.8–412.3)
(Continued)
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TABLE 2 | Continued
Median (95%
confidence
intervals)
Total expenditure on
health (% of GDP)
Total expenditure on
health in current PPP
per capita
General government
expenditure on
health in current PPP
per capita
Private expenditure
on health in current
PPP per capita
Out of pocket
expenditure in
current PPP per
capita
Social security funds
in current PPP per
capita
Turkmenistan 3.1
(2.6–3.5)
172.3
(164.0–210.7)
118.1
(105.6–137.4)
62.1
(55.7–75.9)
62.1
(55.7–75.9)
–
Ukraine 6.7
(6.5–7.0)
410.2
(342.2–486.1)
242.1
(197.5–275.2)
168.1
(143.1–212.5)
156.0
(132.1–198.0)
–
Uzbekistan 5.7
(5.6–6.1)
133.4
(142.7–215.7)
61.5
(66.6–104.0)
74.1
(75.4–112.4)
69.7 (73.0–106.6) –
Sources: World Health Organization-Global Health Estimates-Database (WHO GHE DB).
other similar indicators (44), as these were beyond the scope of
this paper. Therefore, conclusions of this study are limited to
health spending dynamics and its evolution over the long period
of time without any referral to the success rates of individual
systems or their cost-effectiveness / resource allocation efficiency
(45).
RESULTS
This study has revealed a set of findings, which were not
previously observed to a deeper extent in published evidence
(46). In a time-window from the middle of the 1990s toward
recent years, total health expenditure was rising fast in both
groups of countries. While it almost quadrupled among former
socialist countries, in a group of EU15 and few other similar
nations, this growth was even more concerning. It began from
four times higher starting point around $1,600 PPP on average
within the group and reached a value of almost $4,200 PPP in
only two decades.
The graphs below illustrate linear regression models of Total
Health Expenditure % of GDP as a function of time (years). In
general, the models for both the centrally-planned economies
and the market-based economies fit the data well. The regression
line for free-market economies has a steeper gradient than
the one for centrally-planned economies. This is suggestive of
accelerated rising costs over time in the former.
Figure 1 shows that total expenditure on health % of GDP in
both group of countries increased over time with the increase in
the Free-market economies seen to be more rapid. In fact, we
can observe some form of similarity in the patterns of both lines.
Moreover, the “wave” pattern in both lines seem to be identical
for particular years. The level of total expenditure on health in
free market economies, starts at a higher level, compared to the
centrally planned countries and increases at a faster rate over the
time period studied. This is suggestive of both types of economies
being subjected to the same types of economic pressures and
possibly to the strength of the prevailing global economy. Despite
this, the free-market economies’ spending remains steeper than
the centrally-planned ones.
The steeper level of total expenditure on health for the Free-
market as of 1989 market economies, is due mainly to a steep
increase in both the government and private expenditure on
health relative to spending by centrally-planned economies as of
the same date, with the out-of-pocket expenditure and the social
security funds in the same market economies category following
the same steepness.
Moreover, a widening of the gap in expenditure between the
two types of economies over time can be noted. Which seems to
result from a relatively stable low level of social security funds in
the centrally planned group over the years.
Although, the interest was to study the aggregate, results have
also been evaluated and studied at an individual country level.
When one compares the averages over the periods within the
two figures in Figure 2 it is still clear that the levels within the
“Free Market” economies is overall higher in comparison to the
“Centrally Planned” economies. Moreover, when observing the
outliers, Luxembourg, Monaco, Norway and Switzerland in one
group of countries and Czech Republic, Hungary, and Slovenia
in the other group, the range of variation across countries is also
much larger in the “Free Market” economic group which seems
to indicate much more variation within this group of countries
over the years under study.
One can also note, from Figure 2, that there is little fluctuation
in the private expenditure and the out-of-pocket variables
being considered. This implies that variation arises mainly from
differences in general government expenditure.
DISCUSSION
Since 1960s, it became apparent first in the US health system
that average costs of medical care are rising faster than average
monthly income of ordinary citizen. At the macroeconomic
level, over time it became visible that this growth was
almost twice faster compared to economic growth or gross
domestic product disposable within a nation (47). Vast body
of literature has identified as some of the major drivers
of such growth: blossoming of non-communicable prosperity
diseases (48), population aging (49), innovation in medicine (50)
and pharmaceuticals in particular (51), excessive utilization of
hospital diagnostic imaging (52), underutilization of primary care
(53), and preventive measures and inefficient management (54)
among others. This issue of financial sustainability of national
health care systems became prominent inWestern literature (55).
Accordingly, to meet these challenges health economics as an
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FIGURE 1 | Long term upward trends of health expenditure data extrapolated on the entire group of countries as pondered average of annual values.
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FIGURE 2 | (A) Free Market Economy Indicator comparisons Source: World Health Organization- Global Health Estimates - Database (WHO GHE DB). (B) Centrally
Planned Market Economy Indicator comparisons Source: World Health Organization- Global Health Estimates - Database (WHO GHE DB).
interdisciplinary science emerged from American traditions in
academic economics (56, 57).
On the other hand, during the Cold War Era, socialist
countries controlled these health care costs at an unrealistic level
by several ways (58). One of them was a negotiation process
between one central state-owned health insurance fund as a
major purchasing authority for health services and a large tertiary
care hospitals as a core provider of such services. They used
to be paid based on the performance such as total duration of
hospital admissions, number of surgical procedures performed
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or outpatient physician examinations (59). However, due to the
fact that these funds tended to generate debt in most countries
and ongoing fiscal deficits, these services were not covered in
total value, but just as a dominant share of such costs. For the
rest, hospitals themselves had to generate revenues by a variety
of ways but mostly by charging the difference as patient/citizen
participation fees (60).
All of these weaknesses became more prominent after the
beginning of socioeconomic transition (61) in Eastern Europe
since 1991 (62). As these countries moved from the state
controlled model toward market controlled mechanisms, a large
degree of vulnerability occurred both for the citizens in need
(63) and the health system itself (32). This all worsened to a
large extent due to the Russian Federation’s economic recession
reaching its worst-ever level in 1998. This phenomenon dragged
the entire region and central Asia into an ensuing economic
crisis. This was followed by a notorious mortality crisis in Russia
(64) and neighboring nations. Eventually, the situation rapidly
improved in the early 2000s (65).
Difficulties experienced by the variety of national health
systems in this region are closely explained in the published
literature (66). Some authors even went as far as declaring some
countries to be “winners” and others “losers” of transition (66).
This in our opinion is exaggerated because, almost 30 years
after, health policy observations, taught us that each single nation
succeeded to adapt in its own way (67). Health coverage (68),
accessibility and affordability of services and ultimately core
population health outcomes such as longevity, all improved
visibly in Eastern Europe (44).
It should be noted that countries created from former
Yugoslav Republics present a rather distinct case (68). The
former, Yugoslavia, geopolitically outside the Iron Curtain, was
by far the richest socialist country. It deployed the system
of health care provision and financing, which presented a
mixture of Soviet Semashko and Bismarck traditions (69). Its
community health outcomes were mostly outperforming other
similar nations. After the civil wars of its dissolution in 1990s
ended, most countries of the region entered this transition and
health care reforms with approximately one decade delay (70).
Their public health indictors today slightly lag behind Poland
(71), Hungary (72) or Czech Republic (73). However, keeping in
mind contemporary health spending disparity in favor of eastern
EU members as of 2004, their health systems perform quite
satisfactory (74).
Over the years the differences in both the levels of total
expenditure on health (in PPP per capita terms) and the
proportion of total health expenditure as a % of GDP across the
two sets of market economies has increased. Both sets of market
economies have recorded significant increases over the years
within both components of interest. However the increasing
variation between the two sets of countries is clearly noticeable.
Indeed, at a more disaggregated level, both general government
expenditure on health and private expenditure on health within
free market economies reflect the significant increases recorded
over the years. The developments within the expenditure on the
social security funds component over the years also reflect the
above considerations. Whilst recognizing that there might be
divergences in behavior over time for such components, within
the specific countries which make up each of the two groups
under study, the general observations mentioned above apply for
most of the particular countries in question.
CONCLUSION
Variety of governments were leading Eastern European countries
into their transitional health care reforms. This process was
followed by difficult years of poverty, rising socioeconomic
inequalities (75) and system inefficiencies to provide equitable
and affordable medical care to the citizens (76). The ground
assumption of the authorities at some point in time was that
former socialist countries should converge with their Western
counterparts both in terms of health spending and outcomes.
We may witness that these goals have been met only to some
extent (77). Long term trends even depict clear divergent trends
in some health expenditure indicators. Similar phenomenon has
already been described in pharmaceutical spending in previous
findings (78). Judgment of allocative or technical efficiency
of such financial policies is beyond this research. Although,
we may say that historical free-market societies appear to
be rising their ability to invest faster in health care (79),
based on the data observed, we are unable to estimate the
degree of success in public health indicators in particular
nations. However, we may confirm clear presence of obvious
divergent upward trends in total governmental and private
health expenditures between these two groups of countries over
the past two decades. The degree of challenge to the fiscal
sustainability of these health systems will have to be judged for
each single nation, in line with its own local circumstances and
perspectives (80).
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